Avalo Therapeutics Stock Book Value Per Share

AVTX Stock

USD 9.55 0.44 4.40%

Avalo Therapeutics fundamentals help investors to digest information that contributes to Avalo Therapeutics' financial success or failures. It also enables traders to predict the movement of Avalo Stock. The fundamental analysis module provides a way to measure Avalo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avalo Therapeutics stock.

	Last Reported	Projected for Next Year
Book Value Per Share	26.30	24.98
Tangible Book Value Per Share	(11.51)	(10.94)

Book Value Per Share is likely to drop to 24.98 in 2024. Tangible Book Value Per Share is likely to rise to -10.94 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Avalo Therapeutics Company Book Value Per Share Analysis

Avalo Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Avalo Therapeutics Book Value Per Share

2.18 X

Most of Avalo Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avalo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Avalo Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Avalo Therapeutics is extremely important. It helps to project a fair market value of Avalo Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Avalo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avalo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avalo Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Good Will	Net Invested Capital	Net Working Capital	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Long Term Debt	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.78	-0.27	-0.48	0.45	0.57	0.81	0.21	0.63	-0.3	0.83	0.31	0.21	0.38	0.58	-0.25	0.55	0.54	0.45	0.42	-0.06	-0.06
Total Stockholder Equity	0.78		-0.38	-0.35	0.15	-0.04	0.57	0.4	0.46	-0.46	0.66	0.33	0.02	0.18	0.42	-0.26	0.4	0.55	0.42	0.3	-0.11	-0.11
Net Debt	-0.27	-0.38		0.18	-0.18	0.07	-0.62	0.09	-0.77	0.42	0.13	-0.42	0.2	-0.39	-0.75	0.39	-0.26	-0.58	-0.3	-0.61	0.07	0.07
Retained Earnings	-0.48	-0.35	0.18		-0.15	-0.19	-0.37	0.15	-0.24	0.01	-0.1	0.52	0.6	0.41	-0.37	0.81	-0.93	-0.22	-0.84	0.27	0.63	0.63
Accounts Payable	0.45	0.15	-0.18	-0.15		0.61	0.63	-0.06	0.65	0.17	0.41	0.42	0.48	0.44	0.54	-0.33	0.39	0.64	0.43	0.63	0.51	0.51
Total Liab	0.57	-0.04	0.07	-0.19	0.61		0.6	-0.15	0.45	0.17	0.53	0.19	0.45	0.49	0.39	0.03	0.32	0.18	0.16	0.39	0.29	0.29
Total Current Assets	0.81	0.57	-0.62	-0.37	0.63	0.6		-0.03	0.87	-0.18	0.55	0.47	0.24	0.62	0.86	-0.35	0.54	0.69	0.47	0.72	0.18	0.18
Common Stock	0.21	0.4	0.09	0.15	-0.06	-0.15	-0.03		0.01	-0.14	0.22	0.06	0.07	0.08	-0.05	0.15	-0.2	-0.09	-0.19	0.05	0.11	0.11
Current Deferred Revenue	0.63	0.46	-0.77	-0.24	0.65	0.45	0.87	0.01		-0.32	0.33	0.59	0.2	0.66	0.88	-0.32	0.4	0.72	0.38	0.84	0.21	0.21
Short Term Debt	-0.3	-0.46	0.42	0.01	0.17	0.17	-0.18	-0.14	-0.32		-0.28	-0.46	0.22	-0.25	-0.43	0.07	-0.07	-0.46	-0.13	-0.32	0.29	0.29
Net Receivables	0.83	0.66	0.13	-0.1	0.41	0.53	0.55	0.22	0.33	-0.28		0.46	0.53	0.41	0.26	0.11	0.24	0.44	0.21	0.37	0.25	0.25
Net Tangible Assets	0.31	0.33	-0.42	0.52	0.42	0.19	0.47	0.06	0.59	-0.46	0.46		0.67	0.81	0.44	0.31	-0.29	0.63	-0.18	0.89	0.62	0.62
Good Will	0.21	0.02	0.2	0.6	0.48	0.45	0.24	0.07	0.2	0.22	0.53	0.67		0.63	-0.06	0.6	-0.45	0.16	-0.42	0.55	0.82	0.82
Net Invested Capital	0.38	0.18	-0.39	0.41	0.44	0.49	0.62	0.08	0.66	-0.25	0.41	0.81	0.63		0.59	0.38	-0.22	0.36	-0.29	0.9	0.58	0.58
Net Working Capital	0.58	0.42	-0.75	-0.37	0.54	0.39	0.86	-0.05	0.88	-0.43	0.26	0.44	-0.06	0.59		-0.49	0.53	0.73	0.49	0.73	-0.01	-0.01
Intangible Assets	-0.25	-0.26	0.39	0.81	-0.33	0.03	-0.35	0.15	-0.32	0.07	0.11	0.31	0.6	0.38	-0.49		-0.85	-0.52	-0.91	0.06	0.45	0.45
Property Plant Equipment	0.55	0.4	-0.26	-0.93	0.39	0.32	0.54	-0.2	0.4	-0.07	0.24	-0.29	-0.45	-0.22	0.53	-0.85		0.45	0.95	-0.03	-0.39	-0.39
Long Term Debt	0.54	0.55	-0.58	-0.22	0.64	0.18	0.69	-0.09	0.72	-0.46	0.44	0.63	0.16	0.36	0.73	-0.52	0.45		0.59	0.68	0.15	0.15
Short Long Term Debt	0.45	0.42	-0.3	-0.84	0.43	0.16	0.47	-0.19	0.38	-0.13	0.21	-0.18	-0.42	-0.29	0.49	-0.91	0.95	0.59		0.01	-0.3	-0.3
Capital Stock	0.42	0.3	-0.61	0.27	0.63	0.39	0.72	0.05	0.84	-0.32	0.37	0.89	0.55	0.9	0.73	0.06	-0.03	0.68	0.01		0.58	0.58
Capital Surpluse	-0.06	-0.11	0.07	0.63	0.51	0.29	0.18	0.11	0.21	0.29	0.25	0.62	0.82	0.58	-0.01	0.45	-0.39	0.15	-0.3	0.58		1.0
Deferred Long Term Liab	-0.06	-0.11	0.07	0.63	0.51	0.29	0.18	0.11	0.21	0.29	0.25	0.62	0.82	0.58	-0.01	0.45	-0.39	0.15	-0.3	0.58	1.0

Click cells to compare fundamentals

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Competition

Predict Avalo Therapeutics

Book Value Per Share Over Time

Avalo Common Stock Shares Outstanding

Common Stock Shares Outstanding

291,613

At this time, Avalo Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year.

In accordance with the recently published financial statements, the book value per share of Avalo Therapeutics is about 2.177 times. This is 228.06% lower than that of the Biotechnology sector and 100.88% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.89% higher than that of the company.

Avalo Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avalo Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avalo Therapeutics could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics of similar companies.

Avalo Therapeutics is currently under evaluation in book value per share category among its peers.

Avalo Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Avalo Therapeutics from analyzing Avalo Therapeutics' financial statements. These drivers represent accounts that assess Avalo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Avalo Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	112.3M	308.1M	194.0M	47.4M	2.5M	2.4M
Enterprise Value	117.0M	305.8M	175.5M	53.7M	(4.4M)	(4.1M)

Avalo Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avalo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avalo Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Avalo Fundamentals

	Return On Equity	-0.43
	Return On Asset	-0.31
	Operating Margin	(51.65) %
	Current Valuation	23.22 M
	Shares Outstanding	10.46 M
	Shares Owned By Insiders	5.86 %
	Shares Owned By Institutions	64.99 %
	Number Of Shares Shorted	10.06 K
	Price To Book	4.96 X
	Price To Sales	127.48 X
	Revenue	1.92 M
	Gross Profit	(7.94 M)
	EBITDA	(27.95 M)
	Net Income	(31.54 M)
	Cash And Equivalents	11.25 M
	Cash Per Share	1.20 X
	Total Debt	537 K
	Debt To Equity	5.62 %
	Current Ratio	0.98 X
	Book Value Per Share	2.18 X
	Cash Flow From Operations	(30.68 M)
	Short Ratio	0.18 X
	Earnings Per Share	94.42 X
	Target Price	35.0
	Number Of Employees	19
	Beta	1.03
	Market Capitalization	104.53 M
	Total Asset	20.99 M
	Retained Earnings	(335.13 M)
	Working Capital	3.78 M
	Net Asset	20.99 M

About Avalo Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Avalo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avalo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avalo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC